Last reviewed · How we verify

NCT05835557

Physiological Outcomes of High-intensity Interval Training With Post-exercise Blood Flow Restriction

Completed NA Last updated 13 April 2025
What this trial tests

NA trial testing BFR-ST in Exercise Performance in 40 participants. Completed in 30 September 2024.

Timeline
1 July 2023
Primary endpoint
30 September 2024
30 September 2024

Quick facts

Lead sponsorNanyang Technological University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment40
Start date1 July 2023
Primary completion30 September 2024
Estimated completion30 September 2024
Sites1 location across Singapore

Drugs / interventions tested

Conditions studied

Sponsor

Nanyang Technological University

Who can join

Adults 18 to 40, male only, with Exercise Performance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study revolves around the physiological outcomes of using post-exercise blood flow restriction (BFR) with high intensity short interval training (ST) The main aims of this study are to compare (i) aerobic performance outcomes, and (ii) anaerobic and muscular performance outcomes - between 2 groups of participants after either undergoing 3 weeks of ST + post-exercise BFR (BFR-ST) or traditional ST.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Exercise Performance

Currently open trials in the same condition.

Other Nanyang Technological University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05835557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing